ANN ARBOR, Michigan - August 22, 2017 - ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, is pleased to announce the company’s recently featured interview in Mergermarket, a leading provider of forward-looking M&A intelligence and data to M&A professionals and corporations around the world.

In conjunction with the company’s renewed global collaboration agreement with GE Healthcare, successful Nasdaq listing & closing of its initial public offering, ENDRA’s CEO Francois Michelon sat down with Mergermarket’s Senior Life Sciences & Healthcare journalist, William Langbein, to discuss the details.

Michelon explained the springboard of ENDRA’s IPO was to leverage the IP and technology of its laboratory system and bring to market a disruptive technology for the clinical market. Leveraging a world-class customer base including Stanford University and the University of Michigan, ENDRA is now developing a Thermo-Acoustic Enhanced UltraSound (TAEUS™) clinical platform that utilizes RF pulses and ultrasound. The innovative, non-invasive technology is designed to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI – but at a fraction of the cost, on ultrasound. ENDRA’s first application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD), which affects over 1 billion people globally.

In terms of cost, Michelon described ENDRA’s TAEUS™ software-driven platform and its application in diagnosing Non-Alcoholic Fatty Liver Disease (NAFLD). Each of ENDRA’s TAEUS platform applications will require regulatory approvals before ENDRA will be able to sell or license the application. Upon receiving applicable regulatory approval for ENDRA’s NAFLD application, ENDRA expects to sell it as a $40,000 accessory to commercially available ultrasound units, which generally retail for about $100,000. The combination of the TAEUS NAFLD application and a typical ultrasound unit would enable imaging capabilities currently only available on much more expensive MRI or CT scanners. ENDRA believes the price point of its TAEUS application will create a broadly accessible, practical solution. Michelon went on to detail ENDRA’s plans to expand tissue visualization technology through strategic partnerships. GE Healthcare, which signed a partnership with ENDRA last year, has agreed to help introduce ENDRA’s TAEUS technology to GE ultrasound customers, and provide technical advice and support.

According to the Mergermarket interview, Langbein mentioned a recent notable M&A transaction, whereby Stryker paid $702 million to acquire Novadaq Technologies earlier this summer. Novadaq’s approach suggests that enhancements to medical imaging systems are a long-term trend in medical devices. Michelon commented that the Novadaq transaction was consistent with the historical evolution of clinical ultrasound technology since the 1960’s, whereby new technologies developed by small companies like ENDRA have expanded the utility of ultrasound and have been adopted by key ultrasound OEMs, driving M&A activity. ENDRA recently raised $8.6 million in its initial public offering and expects the proceeds to provide ample runway for the initial commercialization of the TAEUS platform in Europe in 2018.

To view the full article of the interview, click here to subscribe to Mergermarket.

About Mergermarket

Mergermarket, an Acuris company, is a subscription-based news wire service catering exclusively to the global investment community. Subscribers include investment banks, private equity firms, venture capital groups, hedge funds, law and accounting firms, and other business advisors, as well as corporations of all sizes in major industries. It has 107,000 readers globally and its website receives more than 100,000 hits a day. Articles are posted to its secure website 24/7 and also delivers via e-mail and mobile alerts. Mergermarket journalists are based in 65 locations across the Americas, Europe, Asia-Pacific, the Middle East and Africa. For more information on Mergermarket click here.

Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235